Workshop Report for Cancer Research: Defining the Shades of Gy: Utilizing the Biological Consequences of Radiotherapy in the Development of New Treatment Approaches—Meeting Viewpoint

Ahmed, Mansoor M.; Coleman, C. Norman; Mendonca, Marc S.; Bentzen, Søren M.; Bhatia, Vikram; Seltzer, S. M.; Goodhead, Dudley T.; Obcemea, Ceferino; Mohan, Radhe; Prise, Kevin M.; Capala, Jacek; Citrin, Deborah E.; Kao, Gary D.; Aryankalayil, Molykutty J.; Eke, Iris; Buchsbaum, Jeffrey C.; Prasanna, Pataje G.S.; Liu, Fei‐Fei; Le, Quynh Thu; Teicher, Beverly A.; Kirsch, David G.; Smart, Dee Dee; Tepper, Joel E.; Formenti, Silvia C.; Haas‐Kogan, Daphne A.; Raben, David; Mitchell, James B.

doi:10.1158/0008-5472.can-17-3760

Cited by 23 publications

(22 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, to date there have been no spectacular successes for this strategy, perhaps due to the complexity of the problem and dearth of well-designed studies. In radiation oncology research, radiation is now considered a “drug” in which the type, dose and fractionation can be varied to produce the desired effect; therefore, it has become important that radiation be considered as an essential participant in precision medicine (9).…”

Section: Discussionmentioning

confidence: 99%

“…Thus, cetuximab with radiation treatment failed to qualify as standard-of-care. Therefore, there remains a tremendous need to develop more biologically targeted drug-radiotherapy combinations as treatments become increasingly customized to patient cohorts or individual patient bio-marker profiles (9).…”

Section: Introductionmentioning

confidence: 99%

“…There continues to be improved understanding of cancer biology and radiation response including gene expression and epigenetic alterations, cellular signaling, protein posttranslational modifications and differences in DNA damage response and repair between tumor and normal tissue (9). These developments open many new critical molecular pathways that can be pharmacologically targeted and exploited in conjunction with radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities: Current Challenges and New Approaches: Report of the Symposium Held at the 63rd Annual Meeting of the Radiation Research Society, 15–18 October 2017; Cancun, Mexico

et al. 2018

Self Cite

View full text Add to dashboard Cite

The National Cancer Institute’s (NCI) Radiation Research Program (RRP) is endeavoring to increase the relevance of preclinical research to improve outcomes of radiation therapy for cancer patients. These efforts include conducting symposia, workshops and educational sessions at annual meetings of professional societies, including the American Association of Physicists in Medicine, American Society of Radiation Oncology, Radiation Research Society (RRS), Radiosurgery Society, Society of Nuclear Medicine and Molecular Imaging, Society for Immunotherapy of Cancer and the American Association of Immunology. A symposium entitled “Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities” was conducted by the NCI’s RRP during the 63rd Annual Meeting of the RRS on October 16, 2017 in Cancun, Mexico. In this symposium, discussions were held to address the challenges in developing radiation-drug combinations, optimal approaches with scientific evidence to replace standard-of-care, approaches to reduce normal tissue toxicities and enhance post-treatment quality-of-life and recent advances in antibody-drug conjugates. The symposium included two broad overview talks followed by two talks illustrating examples of radiation-drug combinations under development. The overview talks identified the essential preclinical infrastructure necessary to accelerate progress in the development of evidence and important challenges in the translation of drug combinations to the clinic from the laboratory. Also addressed, in the example talks (in light of the suggested guidelines and identified challenges), were the development and translation of novel antibody drug conjugates as well as repurposing of drugs to improve efficacy and reduce normal tissue toxicities. Participation among a cross section of clinicians, scientists and scholars-in-training alike who work in this focused area highlighted the importance of continued discussions to identify and address complex challenges in this emerging area in radiation oncology.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities: Current Challenges and New Approaches: Report of the Symposium Held at the 63rd Annual Meeting of the Radiation Research Society, 15–18 October 2017; Cancun, Mexico

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…As is clear from the breadth of this special issue, pediatric radiation therapy is an area of active, global interest and collaboration. In support of this, NCI's Radiation Research Program (RRP) has held workshops on the need to consider dose in new ways to better integrate radiation therapy with the future of molecular oncology 17 . Pediatric radiation therapy is well positioned to address this built on a long history of strong trial enrollment, molecularly focused cancer trials, and a culture of collaboration.…”

Section: Futurementioning

confidence: 99%

NCI support for pediatric radiation therapy: Past, present, and future

Buchsbaum

Bhatia

2020

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

“…Implementation of this intriguing treatment modality requires particular diligence and robust trials that ensure the technology performs and especially demonstrates effective tumor cell killing as we move into the transformational domain of exploiting both the extraordinary technology and biology of the radiation beam. 11…”

mentioning

confidence: 99%